UBS raised the firm’s price target on Edwards Lifesciences (EW) to $90 from $85 and keeps a Neutral rating on the shares. Edwards Lifesciences posted a broad-based beat and raise quarter and raised the full year TAVR guidance to 7%-8%, which UBS views as conservative, the analyst tells investors in a research note. UBS remains on the sidelines for now as it’s still unclear whether the sustainable mid-term TAVR growth trajectory is better than mid-to-high single digits.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EW:
- Edwards Lifesciences price target raised to $84 from $81 at Canaccord
- Edwards Lifesciences upgraded to Outperform at Raymond James
- Edwards Lifesciences Reports Strong Earnings and Growth
- Edwards Lifesciences price target raised to $92 from $88 at Evercore ISI
- Edwards Lifesciences price target raised to $104 from $94 at Goldman Sachs